ÂÜÀòÂÒÂ×

Stefan Gross has been working in the field of biology for over 30 years. Stefan's current role is Vice President Biology at EnLiven Therapeutics, a position they have held since 2020. Prior to this, they were Senior Director of Cell Biology at Pfizer from 2019 to 2018. Before that, they were Senior Director Cell Biology at Array BioPharma Inc., where they were the Head of New Target Discovery and Validation and the project lead on two undisclosed drug discovery programs. From 2014 to 2013, they were Senior Director and Director, Biology at Blueprint Medicines, where they were the project team leader of NTRK small molecule inhibitor program and the head of Immunology and Immuno-oncology initiative. From 2013 to 2010, they were Director, Head of Integrated Lead Discovery (DMP/Ophthamology/Neurosciences) at Novartis Institutes for BioMedical Research, where they were responsible for overseeing disease area portfolios and providing business management and research expertise to drug discovery project teams. From 2010 to 2002, they were Principal Research Investigator at sanofi-aventis, where they were the project team leader on multiple oncology drug discovery programs and the laboratory head of small cell biology-focused research group. From 2002 to 2000, they were Senior Group Leader, Research Investigator, and Senior Research Scientist at Array BioPharma. At Pfizer from 2000 to 1997, they were a Research Scientist. From 1997 to 1991, they were a Postdoctoral Scientist at Howard Hughes Medical Institute and a Graduate Student at University of Wisconsin-Madison.

Stefan Gross obtained their PhD in Cell and Molecular Biology from the University of Wisconsin-Madison between 1991 and 1997. Prior to that, they obtained a BA in Molecular, Cellular and Developmental Biology from the University of Colorado between 1985 and 1990.